Sandu Pharmaceuticals Ltd Financials
Company Logo

Sandu Pharmaceuticals Ltd Financial Statement

Sandu Pharmaceuticals Ltd Income Statement

Quarterly

Annual

*All values are in Rs. Cr

Particulars
Sep 2024
Revenue17.73
Operating Expense16.79
Net Profit0.50
Net Profit Margin2.82
Earning Per Share0.52
EBIDTA0.91
Effective Tax Rate22.11
Invest in Sandu Pharmaceuticals Ltd
₹0 Brokerage*
Open Demat Account
*By signing up you agree to our Terms and Conditions

Sandu Pharmaceuticals Ltd Profit & Loss

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Total Revenue Annual67.28
Operating Expenses Annual64.98
Operating Profit Annual2.72
Interest Annual0.06
Depreciation0.58
Net Profit Annual1.46
Tax Annual0.61

Sandu Pharmaceuticals Ltd Cash Flow

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Cash Flow at the Beginning2.27
Cash Flow from Operations0.76
Cash Flow from Investing-1.31
Cash Flow from Financing-0.72
Cash Flow at the End1

Sandu Pharmaceuticals Ltd Key Ratios

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
PBDIT Margin (%)4.04
PBIT Margin (%)3.18
PBT Margin (%)-49.58
Net PROFIT Margin (%)2.17
Return On Networth / Equity (%)3.66
Return On Networth /Employed (%)5.33
Return On Assets (%)3.65
Total Debt / Equity (X)TBA
Asset Turnover Ratio (%)1.68

Sandu Pharmaceuticals Ltd Balance Sheet

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Fixed Assets Annual17.88
Total Current Assets Annual22.30
Non Current Assets Annual30.12
Total Shareholders Funds Annual40.60
Total Assets Annual52.42

Sandu Pharmaceuticals Ltd Earning Calls

EPS (INR)

Expected

0.52

Reported

1.95

Surprise

275.00%

Jun 2024

EPS beaten by 275.00%

Mar 2024

EPS beaten by -5.56%

Dec 2023

EPS beaten by 1.64%

Get Your FAQs Right

As of Nov 24, 2024, Sandu Pharmaceuticals Ltd has a market capitalization of 55.44 Cr. Value Research classifies it as a Micro-Cap company.
Yes, Sandu Pharmaceuticals Ltd is debt-free with a debt-to-equity ratio of 0.00.
In FY 2023 , Sandu Pharmaceuticals Ltd recorded a total revenue of approximately 67.28 Cr marking a significant milestone in the company's financial performance.
Sandu Pharmaceuticals Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately -0.1% and 0.0% annually, respectively..
Sandu Pharmaceuticals Ltd's current PE ratio is 37.97.
Sandu Pharmaceuticals Ltd's ROCE averaged 5.9% from the FY ending March 2022 to 2024, with a median of 5.9%. It peaked at 6.7% in March 2022, reflecting strong capital efficiency over the period..
Sandu Pharmaceuticals Ltd's latest EBIT is Rs. 2.13 Cr, surpassing the average EBIT of Rs. 2.29 Cr over the 5 years..